Newsroom
Sorted by: Latest
-
图拉科技与全球汽车一级供应商签署里程碑式协议 向其授权动态电机驱动(DMD®)技术
美国加利福尼亚州圣何塞--(BUSINESS WIRE)--(美国商业资讯)-- 动力系统效率领域领军企业、动态电机驱动®(Dynamic Motor Drive®,简称 DMD)技术开发商图拉科技公司今日宣布,与一家全球汽车一级供应商签署知识产权许可协议,授权范围覆盖该供应商旗下全部电驱动产品组合。 根据协议,该一级供应商获得图拉 DMD 专利组合的非独占许可,许可地域包含美国、欧洲及亚洲。本协议是 DMD 技术首次在该供应商全系列电驱动产品上实现商业化落地。 DMD是一项创新的纯软件技术,可在最优工况下精准施加扭矩脉冲,能够降低循环工况能耗 0.5%–2.0%。由于DMD完全通过软件实现,无需改动或新增硬件,供应商与整车厂仅需少量工程投入,即可将该技术集成至现有电驱动系统。该技术可提升电动化车辆的能效:混动车型油耗更低,纯电车型续航更长,且不会增加可感知的噪音与振动。 图拉科技总裁兼首席执行官约翰・富尔斯特表示:“该协议是 DMD 商业化进程中的重要一步,印证了我们的技术能够为各类电动化动力总成应用创造价值。通过向该一级供应商的全系列电驱动产品授权 DMD 专利组合,我们开辟了多条...
-
Tula Technology Signs Landmark Agreement Licensing Dynamic Motor Drive® to Global Tier 1 Supplier
SAN JOSE, Calif.--(BUSINESS WIRE)--Tula Technology signed a non-exclusive IP license agreement with a global Tier 1 automotive supplier covering the supplier’s entire E-drive portfolio....
-
Magnolia Oil & Gas Announces Quarterly Dividend
HOUSTON--(BUSINESS WIRE)--Magnolia Oil & Gas Announces Quarterly Dividend...
-
TCIM Issues Investor Presentation Outlining Why Voya Financial Shareholders Should Vote FOR No Confidence Referendum
NEW YORK--(BUSINESS WIRE)--TOMS Capital Investment Management (“TCIM”), which manages funds that together have an investment representing an approximately 4.65% economic interest in Voya Financial, Inc. (NYSE: VOYA) (“Voya” or the “Company”), today released an investor presentation detailing the case for shareholders to consider and vote on a non-binding resolution. This non-binding resolution allows shareholders to convey unequivocally that they “no longer continue to have confidence in the bo...
-
Latus Bio Announces the Publication of a Predictive Computational Model of Huntington’s Disease (HD) Built on Human Data Along with Validating Preclinical Data, Supporting LTS-201 as a Potential Best-in-Class, Disease-Modifying Therapy for HD
PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the publication of a peer-reviewed study in Nature Communications, titled “Computational modeling and preclinical evaluation support targeting somatic instability for Huntington’s disease treatment.” The study was authored by multiple Latus scientists and led by co-corresponding authors Jang-Ho J. Cha, M.D., Ph.D. and Beverly L. Davidson, Ph.D. The public...
-
Masco Corporation Reports Third Quarter 2026 Results
LIVONIA, Mich.--(BUSINESS WIRE)--Masco Corporation (NYSE: MAS), one of the world’s leading manufacturers of branded home improvement and building products, reported its third quarter 2026 results. 2026 Third Quarter Results On a reported basis, compared to the third quarter 2025: Net sales increased 3 percent to $1,966 million; in local currency and excluding our divestiture of Bristan, net sales increased 4 percent Plumbing Products’ net sales increased 4 percent; in local currency and excludi...
-
KKR Invests $475 Million in Alexandria Real Estate Equities’ Campus Point
NEW YORK & SAN DIEGO--(BUSINESS WIRE)--KKR (NYSE: KKR), a leading global investment firm, and Alexandria Real Estate Equities, Inc. (NYSE: ARE), the leading owner, operator and developer of life science and advanced technology real estate, today announced a $475 million joint venture investment by capital accounts advised by KKR in Alexandria’s majority ownership interest in Campus Point by Alexandria Megacampus™, a nearly 2 million-square-foot life science Megacampus in San Diego, California....
-
D-Wave Customer Shionogi Wins First Place in NEDO Quantum Computing Challenge’s Quality of Life Category
PALO ALTO, Calif. & OSAKA, Japan--(BUSINESS WIRE)--D-Wave Quantum Inc. (NASDAQ: QBTS) ("D-Wave"), the only dual-platform quantum computing company providing both annealing and gate-model systems, software and services, today announced that its customer Shionogi & Co., Ltd. (“Shionogi”) has won first place in the Quality of Life (QOL) category of the NEDO Challenge for its research exploring the application of quantum computing to drug discovery. The award-winning research includes, among ot...
-
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that it has entered into a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate the use of Novocure’s Tumor Treating Fields (TTFields) therapy with chemotherapy and VS-7375, Verastem’s investigational oral, potent and selective KRAS G12D (ON/OFF) inhibitor, to treat locally advanced pancreatic cancer. “Meaningful progress has been made in the treatment of pancreatic cancer and we are prou...
-
Save Money Car Insurance Launches Way Advantage Within 24 Hours
FREMONT, Calif.--(BUSINESS WIRE)--Save Money Car Insurance is now live on Way Advantage. Launched earlier this month, Way had the company live in under 24 hours, giving its customers access to roadside assistance and driver benefits. Save Money Car Insurance helps Oklahoma drivers find affordable auto insurance coverage. Way Advantage (the B2B arm of Way+) gives its drivers more ways to handle everyday car needs from gas cashback to peace of mind perks like roadside and glass breakage benefits....